At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

New Music Alert: @LEEDOBEBMUSIC Drop's Electrifying New Single "SINNER" ft Novo Get ready to groove to the latest offering ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...